Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib
暂无分享,去创建一个
J. Magaud | S. Hayette | I. Tigaud | F. Barraco | F. Nicolini | Q. Le | K. Chabane | M. Michallet | M. Gagnieu | H. Labussière | J. Bernard